Yannick V. H.
- Country
- Belgium
- Department
- Oncology
Research Overview
- Phase 1 Evaluation of ATV-1601 in Patients with Advanced Solid Tumors and Breast Cancer Harboring AKT1 E17K Mutations
- A Phase 3 Randomized Study of Sacituzumab Govitecan and Pembrolizumab Versus Physician's Choice in Triple Negative Breast Cancer with Residual Invasive Disease
- Phase 2 Evaluation of Zelenectide Pevedotin in NECTIN4 Amplified Advanced Breast Cancer with BT8009 Infusion
Data & Insights
Has run more than one trial at 12 of 132 partner sites.
Specializations
Breast Cancer and Solid Tumors
Clinical research activity includes advanced and metastatic breast cancer, triple-negative breast cancer, HER2-negative and HER2-low disease, as well as broader solid tumor oncology. The portfolio also reflects interest in biomarker-defined cancers and treatment-resistant disease settings.
- Advanced and metastatic breast cancer
- Triple-negative and hormone receptor-positive breast cancer
- HER2-low and HER2-negative disease
- Advanced solid tumors
- Biomarker-driven oncology
Therapeutic focus extends across targeted therapy, antibody-drug conjugates, and endocrine-based treatment strategies in difficult-to-treat malignancies.
Thoracic Oncology
Research involvement covers non-small cell lung cancer and small cell lung cancer, including locally advanced, metastatic, and mutation-defined disease. The clinical landscape also includes tumors with EGFR, ALK, ROS1, and KRAS G12C alterations.
- Non-small cell lung cancer
- Small cell lung cancer
- EGFR-mutated and ALK-rearranged disease
- KRAS G12C-mutant solid tumors
- Resectable and unresectable thoracic malignancies
The therapeutic emphasis includes precision oncology and novel systemic approaches for advanced lung cancer.
Gastrointestinal and Hepatobiliary Cancers
Clinical interests span colorectal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic cancer, and biliary tract cancer. The portfolio also includes hepatocellular carcinoma and other advanced digestive system malignancies.
- Colorectal cancer
- Gastric and gastroesophageal junction cancer
- Pancreatic ductal adenocarcinoma
- Biliary tract and hepatobiliary cancers
- Advanced gastrointestinal malignancies
Therapeutic activity is centered on systemic anti-cancer therapy and molecularly selected treatment options for gastrointestinal tumors.
Hematologic Malignancies
Research activity includes acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes. The scope also covers relapsed, refractory, and high-risk hematologic cancers.
- Acute leukemia
- Chronic lymphocytic leukemia and lymphoma
- Multiple myeloma
- Myelodysplastic syndromes
- Relapsed and refractory blood cancers
Therapeutic interest includes immunotherapy, cellular therapy, and novel anti-neoplastic agents for hematologic disease control.
Immune-Mediated, Renal, and Inflammatory Diseases
Clinical research extends beyond oncology into Crohn’s disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, IgA nephropathy, and chronic kidney disease. Additional involvement includes myasthenia gravis, amyotrophic lateral sclerosis, and other immune or neuroinflammatory disorders.
- Inflammatory bowel disease
- Autoimmune rheumatic disease
- Glomerular and chronic kidney disease
- Neuromuscular autoimmune disorders
- Neurodegenerative disease
Therapeutic focus includes immune modulation, renal protection, and anti-inflammatory treatment across chronic systemic disease areas.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.